Roberto Gulminetti
Pavia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
QuantiFERON-TB gold plus in people living with HIV: independence from CD4+ T-cell counts in a low TB-burden setting.
Journal: HIV research & clinical practice
Published: February 04, 2026
Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry.
Journal: Viruses
Published: July 08, 2025
Time fixes everything, but not always: 10 years of persistent PI mutations in the absence of pharmacological pressure-a case report.
Journal: The Journal of antimicrobial chemotherapy
Published: June 27, 2025
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro.
Journal: Antiviral research
Published: February 26, 2025
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study).
Journal: The Journal of antimicrobial chemotherapy
Published: January 09, 2025
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.
Journal: Viruses
Published: March 07, 2024
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study.
Journal: Brain : a journal of neurology
Published: March 03, 2024
Lower aids-related hospitalizations in women living with HIV multidrug resistance.
Journal: AIDS (London, England)
Published: February 01, 2024
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 18, 2023
Pillars of long-term antiretroviral therapy success.
Journal: Pharmacological research
Published: May 20, 2023
Incident diabetes in course of antiretroviral therapy.
Journal: AIDS (London, England)
Published: March 17, 2023
Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.
Journal: Viruses
Published: September 09, 2022
Last Updated: 09/26/2026